deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT03430063

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer

Sponsor: Regeneron Pharmaceuticals

Conditions Advanced Non-Small Cell Lung Carcinoma
Interventions HDREGN2810 SDREGN2810 SDREGN2810/ipi
Updated 15 times since 2018 Last updated: Oct 10, 2022 Started: May 29, 2018 Primary completion: Oct 27, 2021 Completion: Oct 27, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision

Other terminated trials from Regeneron Pharmaceuticals

See all terminations from Regeneron Pharmaceuticals

A PHASE2 clinical study on Advanced Non-Small Cell Lung Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 15 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~May 2020 · 12 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 10 earlier versions

  1. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. May 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Nov 2018 — May 2019 [monthly]

    Recruiting PHASE2

  6. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  8. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  9. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Mar 2018 — Apr 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Regeneron Pharmaceuticals
  • Sanofi
Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Badalona, Spain , Barcelona, Spain , Canton, United States , Gauting, Germany , Gdynia, Poland , Grudziądz, Poland , Herstal, Belgium , Incheon, South Korea , Jeongnam, South Korea , London, United Kingdom and 19 more locations